<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02540538</url>
  </required_header>
  <id_info>
    <org_study_id>HBnr01</org_study_id>
    <secondary_id>2014-000913-30</secondary_id>
    <nct_id>NCT02540538</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of HBAI20 Hepatitis B Vaccine in Naive Adults and Non-responders</brief_title>
  <official_title>Safety and Immunogenicity of HBAI20 Hepatitis B Vaccine in Naive Adults and Non-responders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CyTuVax</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the HBAI20 vaccine is safe and more&#xD;
      immunogenic than the HBVaxPro-10µg in people who have never been vaccinated with a hepatitis&#xD;
      B vaccine and in people who have been vaccinated 6 times with hepatitis B vaccine but do not&#xD;
      have a protective anti hepatitis B antibody titer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rationale: Worldwide, people are suffering from the consequences of Hepatitis B (HB) virus&#xD;
      infection. Currently available vaccines are protective in most of the vaccinees, however, a&#xD;
      small part of the population does not respond to these vaccines (non-responders). A new&#xD;
      adjuvant (AI20) has been developed by CyTuVax to improve the standard Hepatitis B vaccine for&#xD;
      the protection of non-responders. The AI20 adjuvant consists of depot-attached rhuIL-2&#xD;
      (aggregated Interleukin-2 molecules attached to alum), facilitating the slow release of&#xD;
      highly concentrated IL-2 nano aggregates. As shown in preclinical experiments, vaccination of&#xD;
      mice, rats, and rabbits with the new HBAI20 vaccine results in higher and earlier immune&#xD;
      responses to Hepatitis B surface antigen (HBsAg) compared to vaccination with one of the&#xD;
      standard Hepatitis B vaccines. This clinical study will be done in order to assess the safety&#xD;
      of the AI20 adjuvant and test if the AI20 adjuvanted Hepatitis B vaccine induces protective&#xD;
      antibody titers in the vaccinated non-responders.&#xD;
&#xD;
      Objective: In the current study we investigate the safety of the HBAI20 vaccine. Furthermore,&#xD;
      the efficacy of the HBAI20 vaccine in non-responders is investigated.&#xD;
&#xD;
      Study design: Partly double blinded randomized controlled intervention phase I study, partly&#xD;
      open-label phase I study.&#xD;
&#xD;
      Study population: Healthy volunteers (n=24) and registered non-responders (n=12), 18-59 years&#xD;
      old, males and females.&#xD;
&#xD;
      Intervention: The study will include 3 groups. HB vaccine naïve healthy subjects are&#xD;
      randomized into group 1 and 2 and registered non-responders are included in group 3.&#xD;
&#xD;
      &quot;Group 1&quot; subjects receive the standard HB vaccine (HBVaxPro-10µg), &quot;Group 2&quot; and &quot;Group 3&quot;&#xD;
      subjects receive the HBAI20 vaccine. 2 subjects from &quot;Group 3&quot; will constitute &quot;Group 3&#xD;
      pilot&quot; and will start the study 7 days before the start of the remaining &quot;Group 3&quot; subjects.&#xD;
&#xD;
      All study subjects in groups 2 and 3 will receive two vaccinations with the assigned&#xD;
      investigational medical product (IMP) at 0 and 1 month and one regular booster vaccination&#xD;
      with the standard HB vaccine HBVaxPro-10µg 6 months after the first dose according to the&#xD;
      recommended vaccination schedule for HBVaxPro-10µg.&#xD;
&#xD;
      Main study parameters/endpoints: The primary study parameter is the number and intensity of&#xD;
      local and systemic adverse reactions (redness, swelling, impaired movement). The secondary&#xD;
      study parameter is the HBAI20 vaccine immunogenicity as calculated by the median titer,&#xD;
      geometric mean titer, geometric mean titer increase, proportion of subjects with a virus&#xD;
      specific antibody titer measure by the COBAS system of ≥ 10 mIU/ml, and seroconversion rate.&#xD;
      Seroconversion is defined as a four-fold increase in titer or a conversion from seronegative&#xD;
      to an anti-HBsAg antibody titer of more than 10 mIU/ml after vaccinations.&#xD;
&#xD;
      Nature and extent of the burden and risks associated with participation, benefit and group&#xD;
      relatedness: Study subjects will be vaccinated 3 times at 0, 1 and 6 months from the&#xD;
      beginning of the study and invited to the hospital for 8 visits. The risks associated with&#xD;
      participation in this study are considered to be low and comparable with standard vaccines.&#xD;
      Physical discomfort after vaccine administration can occur at the injection site (redness,&#xD;
      swelling, etc.) and systemically (fever, fatigue, headache). Effects are expected to occur&#xD;
      for a short period of time (within the first 4 days after the first and second injection). In&#xD;
      addition subjects may experience adverse reactions to the cytokine component of the adjuvant.&#xD;
      Because of the very low dose of the cytokine component of the adjuvant, which will be&#xD;
      gradually released, the risks are expected to be low. The potential risks of venepuncture for&#xD;
      blood sampling are mild pain and haematoma, and are considered low.&#xD;
&#xD;
      The naïve subjects participating in this study will benefit from participating by receiving&#xD;
      immunization against Hepatitis B. Subjects in the non-responder group may benefit when they&#xD;
      become responders due to the effect of the HBAI20 vaccine.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Subjects With Local and/or General Adverse Events Irrespective of Severity</measure>
    <time_frame>Up to 7 months after first vaccination.</time_frame>
    <description>Subjects will be given a diary for 4 days after the first and second vaccination.&#xD;
Dairy: Local reactions at injection site: Pain (1 to 4), Impaired movement of injected arm (1 to 4), Redness/erythema (cm), Swelling (cm), Induration (cm) General/Systemic adverse events: Fever (temperature measurement), Headache (1 to 4), Fatigue (1 to 4), Muscle pain (1 to 4), Skin rash (1 to 4), Vomiting (1 to 4), Diarrhea (1 to 4).&#xD;
Record medication taken during the study (up to 7 months after the first vaccination).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Subjects With Local and/or General SEVERE Adverse Events</measure>
    <time_frame>Up to 7 months after first vaccination</time_frame>
    <description>Subjects will be given a diary for 4 days after the first and second vaccination.&#xD;
Dairy: Local reactions at injection site: Pain (1 to 4), Impaired movement of injected arm (1 to 4), Redness/erythema (cm), Swelling (cm), Induration (cm) General/Systemic adverse events: Fever (temperature measurement), Headache (1 to 4), Fatigue (1 to 4), Muscle pain (1 to 4), Skin rash (1 to 4), Vomiting (1 to 4), Diarrhea (1 to 4).&#xD;
Record medication taken during the study (up to 7 months after the first vaccination).&#xD;
The laboratory parameters analysed at day 10, 30, 40, 60, 180, and 210 are:&#xD;
Hematology: Hematocrit, Hemoglobin, RBC count, WBC count, Platelet count, Neutrophils, Eosinophils, Basophils, Lymphocytes, and Monocytes. Biochemistry: Creatinine, Albumin, Alkaline Phosphatase, Total Bilirubin, ALT (GPT), AST (GOT), Gamma-Gt, C-Reactive Protein, and TSH/FT4.&#xD;
Urinalysis (day 10, 40, and 210): Clarity, Color, Specific gravity, Leukocytes, Nitrite, pH, Erythrocytes, Albumin, and Glucose.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Seroprotection</measure>
    <time_frame>Day 0, 10, 30, 40, 60, 180, and 210</time_frame>
    <description>Seroprotection at visit number 7, one month after the third vaccination. Anti-HBs antibodies were assayed from serum using a routine chemiluminescence assay (Anti-HBs, Cobas 8000, Roche, Germany). Titres &gt;10 mIU/mL were considered to be seroprotective.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Hepatitis B</condition>
  <arm_group>
    <arm_group_label>HB vaccine naive - HBVaxPro</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects have never been vaccinated with a Hepatitis B vaccine. Subjects are vaccinated with Hepatitis B vaccine HBVaxPro-10ug at day 0, 30, and 180.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HB vaccine naive - HBAI20</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects have never been vaccinated with a Hepatitis B vaccine. Subjects are vaccinated with Hepatitis B vaccine HBAI20 at day 0 and 30, and Hepatitis B vaccine HBVaxPro-10ug at day 180.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-responders - HBAI20</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects have been vaccinated 6 times with a Hepatitis B vaccine without developing a protective immune response, measured as anti Hepatitis B surface antigen antibodies, superior to 10mIU/ml.&#xD;
Subjects are vaccinated with Hepatitis B vaccine HBAI20 at day 0 and 30, and Hepatitis B vaccine HBVaxPro-10ug at day 180.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HBVaxPro</intervention_name>
    <description>3 vaccinations with HBVaxPro-10ug at 0, 30, and 180 days.</description>
    <arm_group_label>HB vaccine naive - HBVaxPro</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HBAI20</intervention_name>
    <description>2 vaccinations with HBAI20 at 0 and 30 days and 1 vaccination with HBVaxPro-10ug at 180 days.</description>
    <arm_group_label>HB vaccine naive - HBAI20</arm_group_label>
    <arm_group_label>Non-responders - HBAI20</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  In good health as determined by the outcome of medical history, physical examination&#xD;
             screening/baseline labs and clinical judgment of the clinical investigator&#xD;
&#xD;
          -  Age 18 to 59 years, inclusive at the time of enrolment&#xD;
&#xD;
          -  Willing and able to adhere to the study regimen&#xD;
&#xD;
          -  Having a signed informed consent form&#xD;
&#xD;
        Non-responders:&#xD;
&#xD;
        - Documented non-responders: Subjects with documented two cycles of Hepatitis B vaccination&#xD;
        (total of 6 vaccinations) and titer analysis that show that they have not developed the&#xD;
        Hepatitis B antibody titer recommended after standard vaccination: anti-HBsAg antibody&#xD;
        titer higher to 10mIU/ml.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any infectious disease at the time of screening and/or enrolment&#xD;
&#xD;
          -  Positive HIV, Hepatitis B virus or Hepatitis C virus serology&#xD;
&#xD;
          -  Positive anti-IL-2 antibody titer&#xD;
&#xD;
          -  Known or suspected immune deficiency&#xD;
&#xD;
          -  Known or suspected disease that influences the immune system including chronic&#xD;
             allergies that require frequent anti-allergy medication, cancer and transplantation&#xD;
             recipients&#xD;
&#xD;
          -  Known or suspected allergy to any of the vaccine components.&#xD;
&#xD;
          -  Dialysis patient&#xD;
&#xD;
          -  History of unusual or severe reactions to any previous vaccination&#xD;
&#xD;
          -  History of any neurologic disorder, including epilepsy and autism&#xD;
&#xD;
          -  Use of medication that influences the immune system (immune suppressive treatment)&#xD;
&#xD;
          -  Any vaccination within 3 months before screening&#xD;
&#xD;
          -  Blood donation within 1 month before screening&#xD;
&#xD;
          -  Administration of plasma (incl. immunoglobulins) or blood products within 12 months&#xD;
             before screening&#xD;
&#xD;
          -  Participation in another clinical trial within 3 months before screening&#xD;
&#xD;
          -  Abnormal pre-treatment laboratory parameters which are clinically relevant according&#xD;
             to the investigator&#xD;
&#xD;
          -  Bleeding disorders, or use of medication for bleeding disorders, and use of&#xD;
             anti-coagulants&#xD;
&#xD;
          -  Female subjects planning to become pregnant or breastfeeding babies until visit 7&#xD;
&#xD;
          -  Females: positive urine pregnancy test. Urine test positive at screening date or&#xD;
             positive urine pregnancy test on the day of vaccination&#xD;
&#xD;
          -  Excessive alcohol or controlled drug use - More than 2 alcohol measures per day (one&#xD;
             alcohol measure is a beer (250ml) or one glass of wine (125ml) or one strong measure&#xD;
             (35ml) or one port/sherry (75ml)). Regular use of controlled drugs&#xD;
&#xD;
        Exclusion criterion for Hepatitis B naïve subjects (groups 1 and 2):&#xD;
&#xD;
        - Previous vaccination with Hepatitis B vaccine&#xD;
&#xD;
        Exclusion criterion for non-responders (group 3):&#xD;
&#xD;
        - Any Hepatitis B vaccination in the last 6 months&#xD;
&#xD;
        Temporary exclusion criterion for vaccination&#xD;
&#xD;
        - Ear temperature &gt; 38.4°C will lead to postponement of participation and vaccination.&#xD;
        Screening may continue when the temperature has normalized.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Astrid ML Oude Lashof, PhD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastricht UMC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Maastricht UMC</name>
      <address>
        <city>Maastricht</city>
        <zip>6202 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <results_reference>
    <citation>Koc ÖM, Savelkoul PHM, van Loo IHM, Peeters A, Oude Lashof AML. Safety and immunogenicity of HBAI20 Hepatitis B vaccine in healthy naïve and nonresponding adults. J Viral Hepat. 2018 Sep;25(9):1048-1056. doi: 10.1111/jvh.12909. Epub 2018 May 9.</citation>
    <PMID>29660190</PMID>
  </results_reference>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>August 25, 2015</study_first_submitted>
  <study_first_submitted_qc>September 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 4, 2015</study_first_posted>
  <results_first_submitted>April 24, 2018</results_first_submitted>
  <results_first_submitted_qc>April 24, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">November 29, 2018</results_first_posted>
  <last_update_submitted>November 29, 2018</last_update_submitted>
  <last_update_submitted_qc>November 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Adjuvants, immunologic</keyword>
  <keyword>Interleukin-2</keyword>
  <keyword>Hepatitis B vaccines</keyword>
  <keyword>Non-responders</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This phase I study involved two trials: a double-blinded RCT in naïve participants and an open-label study in a cohort of true non-responders. At the first visit, a physical examination was performed and blood and urine sampling were taken, and informed written consent was required to participate in the study.</recruitment_details>
      <pre_assignment_details>In RCT, 27 recruits, 3 naïve participants exclusions:&#xD;
1 with liver LFTs abnormalities&#xD;
1 with anti-HBs-AB &gt;10 mIU/mL&#xD;
1 with suspicion of Cushing's syndrome Thus, 24 healthy participants were included.&#xD;
In the open-label study, 10 true non-responders were screened, then included. All participants were between 18 and 59 years of age.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>HB Vaccine Naive - HBVaxPro</title>
          <description>Subjects have never been vaccinated with a Hepatitis B vaccine. Subjects are vaccinated with Hepatitis B vaccine HBVaxPro-10ug at day 0, 30, and 180.&#xD;
HBVaxPro: 3 vaccinations with HBVaxPro-10ug at 0, 30, and 180 days.</description>
        </group>
        <group group_id="P2">
          <title>HB Vaccine Naive - HBAI20</title>
          <description>Subjects have never been vaccinated with a Hepatitis B vaccine. Subjects are vaccinated with Hepatitis B vaccine HBAI20 at day 0 and 30, and Hepatitis B vaccine HBVaxPro-10ug at day 180.&#xD;
HBAI20: 2 vaccinations with HBAI20 at 0 and 30 days and 1 vaccination with HBVaxPro-10ug at 180 days.</description>
        </group>
        <group group_id="P3">
          <title>Non-responders - HBAI20</title>
          <description>Subjects have been vaccinated 6 times with a Hepatitis B vaccine without developing a protective immune response, measured as anti Hepatitis B surface antigen antibodies, superior to 10mIU/ml.&#xD;
Subjects are vaccinated with Hepatitis B vaccine HBAI20 at day 0 and 30, and Hepatitis B vaccine HBVaxPro-10ug at day 180.&#xD;
HBAI20: 2 vaccinations with HBAI20 at 0 and 30 days and 1 vaccination with HBVaxPro-10ug at 180 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>RCT: 27 participants screened, 3 excluded: 1 with LFTs abnormalities, 1 anti-HBs titre &gt;10 mIU/mL, 1 suspected Cushing's syndrome. 24 included. Open-Label: 10 screened and included.</population>
      <group_list>
        <group group_id="B1">
          <title>HB Vaccine Naive - HBVaxPro</title>
          <description>Subjects have never been vaccinated with a Hepatitis B vaccine. Subjects are vaccinated with Hepatitis B vaccine HBVaxPro-10ug at day 0, 30, and 180.&#xD;
HBVaxPro: 3 vaccinations with HBVaxPro-10ug at 0, 30, and 180 days.</description>
        </group>
        <group group_id="B2">
          <title>HB Vaccine Naive - HBAI20</title>
          <description>Subjects have never been vaccinated with a Hepatitis B vaccine. Subjects are vaccinated with Hepatitis B vaccine HBAI20 at day 0 and 30, and Hepatitis B vaccine HBVaxPro-10ug at day 180.&#xD;
HBAI20: 2 vaccinations with HBAI20 at 0 and 30 days and 1 vaccination with HBVaxPro-10ug at 180 days.</description>
        </group>
        <group group_id="B3">
          <title>Non-responders - HBAI20</title>
          <description>Subjects have been vaccinated 6 times with a Hepatitis B vaccine without developing a protective immune response, measured as anti Hepatitis B surface antigen antibodies, superior to 10mIU/ml.&#xD;
Subjects are vaccinated with Hepatitis B vaccine HBAI20 at day 0 and 30, and Hepatitis B vaccine HBVaxPro-10ug at day 180.&#xD;
HBAI20: 2 vaccinations with HBAI20 at 0 and 30 days and 1 vaccination with HBVaxPro-10ug at 180 days.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="10"/>
            <count group_id="B4" value="34"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years (IQR)</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29" lower_limit="22" upper_limit="35"/>
                    <measurement group_id="B2" value="29" lower_limit="22" upper_limit="32"/>
                    <measurement group_id="B3" value="48" lower_limit="42" upper_limit="58"/>
                    <measurement group_id="B4" value="34" lower_limit="23" upper_limit="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25" lower_limit="20" upper_limit="25"/>
                    <measurement group_id="B2" value="23" lower_limit="22" upper_limit="27"/>
                    <measurement group_id="B3" value="29" lower_limit="24" upper_limit="31"/>
                    <measurement group_id="B4" value="25" lower_limit="22" upper_limit="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Anti-HBs Titers &lt; 2 IU/ml</title>
          <description>Number of participants with Anti-HBs titers lower than 2 IU/ml</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Subjects With Local and/or General Adverse Events Irrespective of Severity</title>
        <description>Subjects will be given a diary for 4 days after the first and second vaccination.&#xD;
Dairy: Local reactions at injection site: Pain (1 to 4), Impaired movement of injected arm (1 to 4), Redness/erythema (cm), Swelling (cm), Induration (cm) General/Systemic adverse events: Fever (temperature measurement), Headache (1 to 4), Fatigue (1 to 4), Muscle pain (1 to 4), Skin rash (1 to 4), Vomiting (1 to 4), Diarrhea (1 to 4).&#xD;
Record medication taken during the study (up to 7 months after the first vaccination).</description>
        <time_frame>Up to 7 months after first vaccination.</time_frame>
        <population>RCT: 27 participants screened, 3 excluded: 1 with LFTs abnormalities, 1 anti-HBs titre &gt;10 mIU/mL, 1 suspected Cushing's syndrome. 24 included. Open-Label: 10 screened and included.</population>
        <group_list>
          <group group_id="O1">
            <title>HB Vaccine Naive - HBVaxPro</title>
            <description>Subjects have never been vaccinated with a Hepatitis B vaccine. Subjects are vaccinated with Hepatitis B vaccine HBVaxPro-10ug at day 0, 30, and 180.&#xD;
HBVaxPro: 3 vaccinations with HBVaxPro-10ug at 0, 30, and 180 days.</description>
          </group>
          <group group_id="O2">
            <title>HB Vaccine Naive - HBAI20</title>
            <description>Subjects have never been vaccinated with a Hepatitis B vaccine. Subjects are vaccinated with Hepatitis B vaccine HBAI20 at day 0 and 30, and Hepatitis B vaccine HBVaxPro-10ug at day 180.&#xD;
HBAI20: 2 vaccinations with HBAI20 at 0 and 30 days and 1 vaccination with HBVaxPro-10ug at 180 days.</description>
          </group>
          <group group_id="O3">
            <title>Non-responders - HBAI20</title>
            <description>Subjects have been vaccinated 6 times with a Hepatitis B vaccine without developing a protective immune response, measured as anti Hepatitis B surface antigen antibodies, superior to 10mIU/ml.&#xD;
Subjects are vaccinated with Hepatitis B vaccine HBAI20 at day 0 and 30, and Hepatitis B vaccine HBVaxPro-10ug at day 180.&#xD;
HBAI20: 2 vaccinations with HBAI20 at 0 and 30 days and 1 vaccination with HBVaxPro-10ug at 180 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects With Local and/or General Adverse Events Irrespective of Severity</title>
          <description>Subjects will be given a diary for 4 days after the first and second vaccination.&#xD;
Dairy: Local reactions at injection site: Pain (1 to 4), Impaired movement of injected arm (1 to 4), Redness/erythema (cm), Swelling (cm), Induration (cm) General/Systemic adverse events: Fever (temperature measurement), Headache (1 to 4), Fatigue (1 to 4), Muscle pain (1 to 4), Skin rash (1 to 4), Vomiting (1 to 4), Diarrhea (1 to 4).&#xD;
Record medication taken during the study (up to 7 months after the first vaccination).</description>
          <population>RCT: 27 participants screened, 3 excluded: 1 with LFTs abnormalities, 1 anti-HBs titre &gt;10 mIU/mL, 1 suspected Cushing's syndrome. 24 included. Open-Label: 10 screened and included.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain at the injection site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Impaired movement of injected arm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness/Erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Subjects With Local and/or General SEVERE Adverse Events</title>
        <description>Subjects will be given a diary for 4 days after the first and second vaccination.&#xD;
Dairy: Local reactions at injection site: Pain (1 to 4), Impaired movement of injected arm (1 to 4), Redness/erythema (cm), Swelling (cm), Induration (cm) General/Systemic adverse events: Fever (temperature measurement), Headache (1 to 4), Fatigue (1 to 4), Muscle pain (1 to 4), Skin rash (1 to 4), Vomiting (1 to 4), Diarrhea (1 to 4).&#xD;
Record medication taken during the study (up to 7 months after the first vaccination).&#xD;
The laboratory parameters analysed at day 10, 30, 40, 60, 180, and 210 are:&#xD;
Hematology: Hematocrit, Hemoglobin, RBC count, WBC count, Platelet count, Neutrophils, Eosinophils, Basophils, Lymphocytes, and Monocytes. Biochemistry: Creatinine, Albumin, Alkaline Phosphatase, Total Bilirubin, ALT (GPT), AST (GOT), Gamma-Gt, C-Reactive Protein, and TSH/FT4.&#xD;
Urinalysis (day 10, 40, and 210): Clarity, Color, Specific gravity, Leukocytes, Nitrite, pH, Erythrocytes, Albumin, and Glucose.</description>
        <time_frame>Up to 7 months after first vaccination</time_frame>
        <population>RCT: 27 participants screened, 3 excluded: 1 with LFTs abnormalities, 1 anti-HBs titre &gt;10 mIU/mL, 1 suspected Cushing's syndrome. 24 included. Open-Label: 10 screened and included.</population>
        <group_list>
          <group group_id="O1">
            <title>HB Vaccine Naive - HBVaxPro</title>
            <description>Subjects have never been vaccinated with a Hepatitis B vaccine. Subjects are vaccinated with Hepatitis B vaccine HBVaxPro-10ug at day 0, 30, and 180.&#xD;
HBVaxPro: 3 vaccinations with HBVaxPro-10ug at 0, 30, and 180 days.</description>
          </group>
          <group group_id="O2">
            <title>HB Vaccine Naive - HBAI20</title>
            <description>Subjects have never been vaccinated with a Hepatitis B vaccine. Subjects are vaccinated with Hepatitis B vaccine HBAI20 at day 0 and 30, and Hepatitis B vaccine HBVaxPro-10ug at day 180.&#xD;
HBAI20: 2 vaccinations with HBAI20 at 0 and 30 days and 1 vaccination with HBVaxPro-10ug at 180 days.</description>
          </group>
          <group group_id="O3">
            <title>Non-responders - HBAI20</title>
            <description>Subjects have been vaccinated 6 times with a Hepatitis B vaccine without developing a protective immune response, measured as anti Hepatitis B surface antigen antibodies, superior to 10mIU/ml.&#xD;
Subjects are vaccinated with Hepatitis B vaccine HBAI20 at day 0 and 30, and Hepatitis B vaccine HBVaxPro-10ug at day 180.&#xD;
HBAI20: 2 vaccinations with HBAI20 at 0 and 30 days and 1 vaccination with HBVaxPro-10ug at 180 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects With Local and/or General SEVERE Adverse Events</title>
          <description>Subjects will be given a diary for 4 days after the first and second vaccination.&#xD;
Dairy: Local reactions at injection site: Pain (1 to 4), Impaired movement of injected arm (1 to 4), Redness/erythema (cm), Swelling (cm), Induration (cm) General/Systemic adverse events: Fever (temperature measurement), Headache (1 to 4), Fatigue (1 to 4), Muscle pain (1 to 4), Skin rash (1 to 4), Vomiting (1 to 4), Diarrhea (1 to 4).&#xD;
Record medication taken during the study (up to 7 months after the first vaccination).&#xD;
The laboratory parameters analysed at day 10, 30, 40, 60, 180, and 210 are:&#xD;
Hematology: Hematocrit, Hemoglobin, RBC count, WBC count, Platelet count, Neutrophils, Eosinophils, Basophils, Lymphocytes, and Monocytes. Biochemistry: Creatinine, Albumin, Alkaline Phosphatase, Total Bilirubin, ALT (GPT), AST (GOT), Gamma-Gt, C-Reactive Protein, and TSH/FT4.&#xD;
Urinalysis (day 10, 40, and 210): Clarity, Color, Specific gravity, Leukocytes, Nitrite, pH, Erythrocytes, Albumin, and Glucose.</description>
          <population>RCT: 27 participants screened, 3 excluded: 1 with LFTs abnormalities, 1 anti-HBs titre &gt;10 mIU/mL, 1 suspected Cushing's syndrome. 24 included. Open-Label: 10 screened and included.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Severe pain at injection site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe impaired movement of injected arm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sever swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe induration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Seroprotection</title>
        <description>Seroprotection at visit number 7, one month after the third vaccination. Anti-HBs antibodies were assayed from serum using a routine chemiluminescence assay (Anti-HBs, Cobas 8000, Roche, Germany). Titres &gt;10 mIU/mL were considered to be seroprotective.</description>
        <time_frame>Day 0, 10, 30, 40, 60, 180, and 210</time_frame>
        <population>RCT: 27 participants screened, 3 excluded: 1 with LFTs abnormalities, 1 anti-HBs titre &gt;10 mIU/mL, 1 suspected Cushing's syndrome. 24 included. Open-Label: 10 screened and included.</population>
        <group_list>
          <group group_id="O1">
            <title>HB Vaccine Naive - HBVaxPro</title>
            <description>Subjects have never been vaccinated with a Hepatitis B vaccine. Subjects are vaccinated with Hepatitis B vaccine HBVaxPro-10ug at day 0, 30, and 180.&#xD;
HBVaxPro: 3 vaccinations with HBVaxPro-10ug at 0, 30, and 180 days.</description>
          </group>
          <group group_id="O2">
            <title>HB Vaccine Naive - HBAI20</title>
            <description>Subjects have never been vaccinated with a Hepatitis B vaccine. Subjects are vaccinated with Hepatitis B vaccine HBAI20 at day 0 and 30, and Hepatitis B vaccine HBVaxPro-10ug at day 180.&#xD;
HBAI20: 2 vaccinations with HBAI20 at 0 and 30 days and 1 vaccination with HBVaxPro-10ug at 180 days.</description>
          </group>
          <group group_id="O3">
            <title>Non-responders - HBAI20</title>
            <description>Subjects have been vaccinated 6 times with a Hepatitis B vaccine without developing a protective immune response, measured as anti Hepatitis B surface antigen antibodies, superior to 10mIU/ml.&#xD;
Subjects are vaccinated with Hepatitis B vaccine HBAI20 at day 0 and 30, and Hepatitis B vaccine HBVaxPro-10ug at day 180.&#xD;
HBAI20: 2 vaccinations with HBAI20 at 0 and 30 days and 1 vaccination with HBVaxPro-10ug at 180 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Seroprotection</title>
          <description>Seroprotection at visit number 7, one month after the third vaccination. Anti-HBs antibodies were assayed from serum using a routine chemiluminescence assay (Anti-HBs, Cobas 8000, Roche, Germany). Titres &gt;10 mIU/mL were considered to be seroprotective.</description>
          <population>RCT: 27 participants screened, 3 excluded: 1 with LFTs abnormalities, 1 anti-HBs titre &gt;10 mIU/mL, 1 suspected Cushing's syndrome. 24 included. Open-Label: 10 screened and included.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 180</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 210</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 7 months after first vaccination</time_frame>
      <group_list>
        <group group_id="E1">
          <title>HB Vaccine Naive - HBVaxPro</title>
          <description>Subjects have never been vaccinated with a Hepatitis B vaccine. Subjects are vaccinated with Hepatitis B vaccine HBVaxPro-10ug at day 0, 30, and 180.&#xD;
HBVaxPro: 3 vaccinations with HBVaxPro-10ug at 0, 30, and 180 days.</description>
        </group>
        <group group_id="E2">
          <title>HB Vaccine Naive - HBAI20</title>
          <description>Subjects have never been vaccinated with a Hepatitis B vaccine. Subjects are vaccinated with Hepatitis B vaccine HBAI20 at day 0 and 30, and Hepatitis B vaccine HBVaxPro-10ug at day 180.&#xD;
HBAI20: 2 vaccinations with HBAI20 at 0 and 30 days and 1 vaccination with HBVaxPro-10ug at 180 days.</description>
        </group>
        <group group_id="E3">
          <title>Non-responders - HBAI20</title>
          <description>Subjects have been vaccinated 6 times with a Hepatitis B vaccine without developing a protective immune response, measured as anti Hepatitis B surface antigen antibodies, superior to 10mIU/ml.&#xD;
Subjects are vaccinated with Hepatitis B vaccine HBAI20 at day 0 and 30, and Hepatitis B vaccine HBVaxPro-10ug at day 180.&#xD;
HBAI20: 2 vaccinations with HBAI20 at 0 and 30 days and 1 vaccination with HBVaxPro-10ug at 180 days.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Unsolicited symptoms</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>We are aware of the limitations of the small study population when drawing the tentative conclusions from this study.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Astrid ML Oude Lashof, MD, PHD</name_or_title>
      <organization>MaastrichtUMC</organization>
      <phone>0031433876644</phone>
      <email>a.oudelashof@mumc.nl</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

